Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT500 in Metabolic Dysfunction-associated Steatotic Liver Disease
NCT07462455Phase 1Not yet recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azithromycin in metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Events, Serious Adverse Events and 11 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
azithromycin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07462455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462455.